Division of Clinical Pharmacology and Toxicology, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada.
Reprod Toxicol. 2010 Jun;29(3):353-60. doi: 10.1016/j.reprotox.2010.01.008. Epub 2010 Jan 22.
There is a dearth of information on paternal drug exposure at the time of conception. The Motherisk Program, established in 1985, is a teratology information and clinical consultation service on drug safety during pregnancy and lactation, as well as paternal exposure (PEx). Here, we reviewed for the first time our experience with PEx.
This was an observational retrospective cohort study using a prospectively collected database. Telephone counselling records from January 2002 to December 2007, inclusive, were screened to identify cases concerning PEx.
Of a total of 188,188 counselling requests over these 6 years, 301 (0.16%) pertained to PEx. Counselling was most frequently sought on methotrexate, finasteride, prednisone and azathioprine. For many drugs, limited or no information was available on PEx.
Paternal exposure represents a small fraction of counselling requests to Motherisk. Our findings suggest that there is an ongoing need for information on paternal drug exposure.
关于受孕时父亲的药物暴露情况，相关信息十分匮乏。1985 年成立的 Motherisk 项目是一个关于孕期和哺乳期药物安全性以及父亲暴露（PEx）的毒理学信息和临床咨询服务。在这里，我们首次回顾了我们在 PEx 方面的经验。
这是一项使用前瞻性收集数据库的观察性回顾性队列研究。对 2002 年 1 月至 2007 年 12 月期间的电话咨询记录进行筛选，以确定与 PEx 相关的案例。
在这 6 年期间，总共 188188 次咨询请求中，有 301 次（0.16%）与 PEx 相关。咨询最常涉及甲氨蝶呤、非那雄胺、泼尼松和硫唑嘌呤。对于许多药物，关于 PEx 的信息有限或没有。
父亲暴露仅占 Motherisk 咨询请求的一小部分。我们的研究结果表明，人们对父亲药物暴露的信息仍有持续需求。
